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Summary
Daptomycin is a lipopeptide antibiotic produced by
a nonribosomal peptide synthetase (NRPS) in Strepto-
myces roseosporus. The holoenzyme is composed of
three subunits, encoded by the dptA, dptBC, and dptD
genes, each responsible for incorporating particular
amino acids into the peptide. We introduced expres-
sion plasmids carrying dptD or NRPS genes encoding
subunits from two related lipopeptide biosynthetic
pathways into a daptomycin nonproducing strain of
S. roseosporus harboring a deletion of dptD. All con-
structs successfully complemented the deletion in
trans, generating three peptide cores related to dapto-
mycin. When these were coupled with incomplete
methylation of 1 amino acid and natural variation in
the lipid side chain, 18 lipopeptides were generated.
Substantial amounts of nine of these compounds
were readily obtained by fermentation, and all dis-
played antibacterial activity against gram-positive
pathogens.
Introduction
Cubicin (daptomycin-for-injection) is a lipopeptide anti-
biotic approved in the United States for treatment of skin
and skin structure infections caused by gram-positive
pathogens [1], including methicillin-resistant or vanco-
mycin-resistant Staphylococcus aureus [2–5]. The ac-
tive principle in Cubicin is daptomycin, a semisynthetic
antibiotic produced by fermentation of S. roseosporus.
Daptomycin is a member of the A21978C family of
acidic lipodepsipeptides [6]. These have a common 13
amino acid core cyclized by an intramolecular ester
bond to make a 10-membered ring with a 3 residue
side chain; attachment of different fatty acids to the
N-terminal residue in the chain results in the predomi-
nant C1, C2, and C3 factors (Figure 1). To produce dapto-
mycin, decanoic acid is provided in the medium during
fermentation to drive biosynthesis toward the n-dec-
anoyl product [7]. A21978C is produced exclusively by
S. roseosporus, but similar compounds, the calcium-
*Correspondence: rbaltz@cubist.comdependent antibiotic (CDA) [8, 9] and members of the
A54145 family [6, 10], are synthesized by S. coelicolor
and S. fradiae, respectively (Figure 1).
Daptomycin is a complex molecule, and there have
been a number of recent NMR studies aimed at defining
its biologically active conformation [11–13]. The chal-
lenging nature of its structure has resulted in only limited
attempts at synthesis and evaluation of daptomycin de-
rivatives. Modifications of the acyl tail or derivatization
at the d-amino group of ornithine (Orn) have been suc-
cessful [14–16], but these peripheral alterations have
not yet yielded a compound with improved antibacterial
properties compared to daptomycin. Total synthesis of
an analog differing from daptomycin by substitution of
Glu for 3-methyl-glutamic acid (3mGlu) at position 12
has recently been achieved through the use of isolated
CDA thioesterase (cyclase) [17]. This approach enabled
replacement of the acidic amino acid residues with Asn
or Gln, and the results highlighted the importance of
Asp7 and Asp9 for antibacterial activity.
In S. roseosporus, daptomycin is synthesized by a
nonribosomal peptide synthetase (NRPS) via a thiotem-
plate mechanism [18–20]. NRPSs are typically com-
posed of several subunits, each divided into a set of
modules. An individual module is minimally comprised
of adenylation (A), condensation (C), and thiolation (T)
domains, and, collectively, the modules are responsible
for recognizing specific amino acids and assembling
them in the correct sequence. Modules can activate
nonproteinogenic amino acids such as the kynurenine
(Kyn) and Orn found in daptomycin, and they may in-
clude additional domains that modify the amino acids;
e.g., epimerase (E) domains convert L-amino acids into
their D-isomers. The specificity of the modules within
the subunits and the order of amino acids in the peptide
are generally colinear, and the last module has a thioes-
terase (Te) domain that releases the mature peptide
from the enzyme.
The daptomycin biosynthetic gene cluster from S.
roseosporus includes three genes, dptA, dptBC, and
dptD, which encode the multimodular NRPS subunits
(DptA, DptBC, and DptD) for assembling the peptide
core (Figure 1). Other genes nearby are likely to be
involved in coupling branched chain fatty acids to the
N-terminal Trp1 (dptE, dptF), error correction (dptH), or
incorporation of 3mGlu12 and Kyn13 (dptI, dptJ) [21].
The cloned dpt gene cluster provides an opportunity
to study daptomycin biosynthesis and to explore
methods to build novel lipopetides by pathway engi-
neering. This is essential for compounds that are com-
mercially generated through fermentation. The ordered
nature of nonribosomal peptide assembly lends itself
well to genetic manipulation by domain or module ex-
change [22, 23]. Another approach, successful for engi-
neering polyketides [24, 25] but not reported for pep-
tides in vivo, is the substitution of entire subunits to
create hybrid pathways and compounds. Here, we de-
scribe experiments in which genes encoding NRPS sub-
units from two other lipopeptide pathways were ex-
pressed in S. roseosporus, leading to the production
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270Figure 1. Lipopeptide Structures, Maps of the Daptomycin Biosynthetic Gene Cluster, and Expression Plasmids
A21978C, CDA, and A54145 are shown at the top. Amino acids incorporated by subunits DptA, DptBC, and DptD are delimited by dotted lines
for daptomycin; those incorporated by CdaPS3 and LptD are indicated likewise for CDA and A54145. Abbreviations: hAsn, hydroxyasparagine;
hPG, hydroxyphenylglycine; Sar, sarcosine; mOAsp, methoxy-Asp; others are as in the text. A21978C includes all acyl tail variants, although
subscripts may be used for clarity; e.g., A21978C1. The dpt genes are indicated by letter above the corresponding arrow on the scaled map at
the center. Portions of the cda and lpt pathways (same scale as for dpt) used in complementation plasmids as well as pHM11a are shown at
the bottom. Genes downstream of cdaPS3 represented by block arrows (left to right): SCO3233 (Te), hasP (phosphotransferase), SCO3235,
asnO (hydroxylase), and SCO3237. Genes downstream of lptD: lptG, lptH (Te), lptJ, lptK (O-MTase), lptL (Asn hydroxylase), lptM, and lptN.of novel active analogs and further understanding of
structure-activity relationships within the daptomycin
molecule.
Results
Homologous Complementation: The dptD System
We first determined if complementation of a deletion in
a multisubunit enzyme gene cluster could be achieved
in trans by NRPS DNA introduced at an ectopic location.
The dptD gene, encoding the last subunit of daptomycin
NRPS, is comprised of the modules for incorporating
3mGlu and Kyn as well as the terminal Te domain (Fig-
ure 1). A DdptD deletion strain (UA378, Table 1) was
generated in S. roseosporus UA117, a daptomycin pro-
ducer, by replacement of dptD with a resistance marker.
UA378 was confirmed to be blocked in A21978C pro-
duction by HPLC analysis of shake flask fermentations
(Figures 2A and 2B). The coding region of dptD was
cloned under control of the strong constitutive ermEp*
promoter in pHM11a [26], an E. coli/streptomycete shut-
tle vector allowing for conjugative transfer and chromo-
somal integration at the attIS117 site. The resulting plas-
mid, pRB04, was introduced into the DdptD host, and
exconjugants were characterized for lipopeptide pro-
duction in shake flasks and compared with the control
strain. While UA378 with pHM11a vector alone producedno A21978C, typical production was restored in trans-
formants with pRB04 (Figure 2C). The yield of UA383
was very similar to that of UA374, a UA117+pHM11a
control (2026 7 mg/l versus 2106 7 mg/l). These results
showed that an NRPS subunit expressed ectopically
under heterologous control could complement the re-
mainder of the native enzyme complex in vivo. The
very efficient functional restoration by pRB04 included
not only the 3mGlu- and Kyn-incorporating activities of
modules 12 and 13, but also the hydrolytic activity of
Table 1. Key S. roseosporus Strains and Plasmids
Strains Genotypea Lipopeptides Produced
UA117 rpsL7 (Smr) A21978C
UA374 UA117 (pHM11a) A21978C
UA378 UA117 DdptD::ermE (none)
UA383 UA378 (pRB04) A21978C
UA416 UA378 (pMF26) A21978C(mGlu/Glu12Trp13)
UA385 UA378 (pMF23) A21978C(mGlu/Glu12Trp13)
UA384 UA378 (pMF22) A21978C(mGlu/Glu12Trp13)
UA451 UA378 (pMF30) A21978C(mGlu/Glu12Ile/Val13)
UA376 UA117 (pMF22) A21978C, A21978C(mGlu/
Glu12Trp13)
UA377 UA117 (pMF23) A21978C, A21978C(mGlu/
Glu12Trp13)
a Indicated by a host strain and plasmid (parenthetic), e.g., UA374
was constructed by integration of pHM11a into UA117.
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Production
(A–G) Absorbance at 224 nm was plotted with
a (A–F) 0–0.6 AU or a (G) 0–0.1 AU vertical
scale. Compounds and strains for which
each panel is representative are listed; the
strain associated with the chromatogram
shown is in bold. (A) Native A21978C profile
and production levels in S. roseosporus
UA374 or UA117. Retention times (Rts) of C1,
C2, and C3 factors = 10.8, 11.3, 11.7 min, re-
spectively. (B) UA378 (DdptD). (C) UA383
(UA378 + dptD). (D) UA416 (UA378 + cdaPS3).
Peak Rts were 11.2, 11.6, and 12.0 min. (E)
UA384 (UA378 + cdaPS3). (F) UA376 (UA117 +
cdaPS3). The complex profile includes those
of A21978C, A21978C(Trp13), and a third set
of peaks that was slightly more polar than
A21978C. LC-MS analysis of the new set indi-
cated molecular ions (MH+) at m/z 1651.7,
1665.7, and 1679.7 that are consistent with un-
cyclized A21978C lipopeptides or compounds
produced by hydrolysis of the ester bond or
one of the peptide bonds of A21978C, as has
been reported for daptomycin [41, 42]. (G)
UA451 (UA378 + lptD). The new, complex set
of products includes A21978C(Ile/Val13).
Peaks at Rt = 14.2 and 14.9 min in all panels
are unrelated peptidic compounds (M. Chu
andJ.-Q. Gu, personal communication) whose
presence is not qualititatively affected by the
current manipulations.the Te domain that is needed to cyclize and release the
mature peptide.
Heterologous Complementation: Novel Compounds
Introduction of subunits that bring substitutions into the
peptide core would generate analogs of daptomycin to
facilitate elucidation of structure-activity relationships,
as well as provide a means to produce the desired deriv-
atives by fermentation. The lipopeptides CDA and
A54145 are also synthesized by NRPSs, and the last
two residues in each compound are incorporated by
a terminal dimodular subunit like DptD: where DptD
incorporates 3mGlu-Kyn in daptomycin, CdaPS3 (en-
coded by cdaPS3 in S. coelicolor [9]) incorporates
Glu/3mGlu-Trp in CDA, and LptD (encoded by lptD in
S. fradiae [27]) incorporates Glu/3mGlu-Ileand, ata lowerfrequency, Glu/3mGlu-Val in A54145 (Figure 1). For suc-
cessful complementation, CdaPS3 and LptD must form
functional multienzyme complexes with DptA and
DptBC; the C domains at the start of the replacement
subunits must accept a nonnative nascent peptide
terminating in a heterologous amino acid, and the Te
domains must cyclize hybrid substrates that differ sub-
stantially from their native peptides. The end of DptBC
and the start of DptD, and the corresponding regions in
the Cda and Lpt proteins, are similar in organization
and sequence (Figure 3). The upstream subunits (donor)
end at an E domain, while the downstream subunits (ac-
ceptor) begin with a CII domain, a type generally follow-
ing modules incorporating D or achiral amino acids
[21]. At the sequence level, there are short extensions
or docking sites that discriminate subunit-terminatingFigure 3. Intersubunit Docking Sites
(A) Domain organization. C, CII, A, T, E, and
Te domains are described in the text.
(B) Terminal peptides on adjoining subunits.
Hydrophilic residues are underlined, and
acidic residues are shaded. Sequences in-
clude: Cda (GenBank AL035654, AL035707),
Dpt (GenBank AY787762), Lpt (GenBank
DQ118863), and tyrocidine (Tyc) proteins
(GenBank AF004835). An asterisk indicates
conserved amino acids; hyphens are inserted
to facilitate alignment of the terminal con-
served amino acid residues of the subunits,
as indicated at the far left and right.
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272Table 2. Physicochemical Characteristics of A21978C and Recombinant Derivatives
Molecular Weights of C1–3 Analogs Molecular Ions (MH+)
Observed by LC-MSStrain Lipopeptide Products lmax C1, C2, C3
UA374 A21978C 224, 262, 365 1633.7, 1647.7, 1661.7 1634.7, 1648.7, 1662.7
UA383 A21978C 224, 262, 365 1633.7, 1647.7, 1661.7 1634.7, 1648.7, 1662.7
UA384, UA385,
and UA416
A21978C(mGlu12Trp13) 220, 280, 288 1629.7, 1643.7, 1657.7 1616.0, 1630.4
A21978C(Glu12Trp13) 220, 280, 288 1615.7, 1629.7, 1643.7 1644.0, 1658.0
UA451 A21978C(mGlu12Ile13) 220, 280, 288 1556.7, 1570.8, 1584.8 1529.0, 1543.0,
A21978C(mGlu12Val13) 220, 280, 288 1542.7, 1556.7, 1570.8 1557.0, 1571.0,
A21978C(Glu12Ile13) 220, 280, 288 1542.7, 1556.7, 1570.8 1585.0
A21978C(Glu12Val13) 220, 280, 288 1528.7, 1542.7, 1556.7domains from those that are internal. There is a very
strong bias for hydrophilic, including acidic, residues
among the w25 C-terminal amino acids (starting at the
‘‘TPS’’ motif), and for hydrophilic residues among the
w15 N-terminal amino acids (ending at the ‘‘PLQEG’’
motif). The similarities in the features of the three sub-
units prompted the investigation of producing daptomy-
cin analogs with substitutions of Kyn by another bulky ar-
omatic residue, Trp, or by smaller aliphatic amino acids,
Ile or Val.
The cdaPS3 gene, present in plasmid pMF26, was in-
troduced into UA378, and shake flask fermentations
from the recombinant UA416 were analyzed. A family of
compounds with UV and mass spectra consistent with
analogs of A21978C in which Kyn has been replaced by
Trp (A21978C[Trp13]) was detected by HPLC-MS (Fig-
ure 2D; Table 2). UA416 produced 50% as much lipo-
peptide as UA374, containing pHM11a alone (70 mg/l
versus 142 mg/l) in a 7 liter fermentation, and provided
material for structure confirmation and biological evalu-
ation. Comparison of the amide and aromatic regions of
the 1H NMR spectra of the purified A21978C(Trp13) ana-
logs with those of the A21978C lipopeptides clearly
showed the absence of the Kyn signals and the appear-
ance of a new set of signals, as expected for an additional
Trp residue. Detailed analysis of the mass spectra of
each of the purified Trp-containing compounds indi-
cated that these were 5:1 mixtures of 3mGlu12- and
Glu12-containing analogs, A21978C(Trp13) and A21978C
(Glu12Trp13), respectively, with the same acyl tails (exhib-
iting the same acyl-Trp losses upon fragmentation) that
had cochromatographed during purification. The pres-
ence of A21978C(Trp13) factors as major products was
noteworthy, as the methyltransferase (MTase)-encoding
gene proposed for methylation of Glu in CDA [9] was not
introduced into S. roseosporus. This indicated that the
MTase encoded by dptI and responsible for conversion
of Glu to 3mGlu in A21978C [21] could accommodate
the hybrid peptide. The presence of unmethylated com-
pounds, however, also suggests that the S. roseosporus
enzyme worked less efficiently with the hybrid, as Glu12
analogs of A21978C have not been observed in control
fermentations.
In addition to pMF26, two other plasmids containing
cdaPS3 and flanking genes were tested in S. roseospo-
rus. Plasmid pMF23 had an extra gene for a putative
proof-reading Te (SCO3233), whereas pMF22 had five
more genes, including asnO and hasP, which encode
enzymes that are likely to catalyze the hydroxylationand phosphorylation on Asn in CDA [9] (Figure 1). Strains
with these plasmids (Table 1) produced A21978C(Trp13)
analogs in shake flasks, but despite the inclusion of
genes for potential Asn-modifying enzymes in pMF22,
no phosphorylated or hydroxylated compounds were
observed (Figure 2E).
Plasmids pMF22 and pMF23 were also tested in
UA117, which has a complete dpt pathway. HPLC data
from recombinants UA376 and UA377 both showed
complex patterns within which profiles characteristic
of the native A21978C factors and of the novel
A21978C(Trp13) factors were discernible, along with
other lipopeptide components that require further char-
acterization (Figure 2F). The total amount of lipopeptide
detected was the same or slightly greater (106% for
UA377; 121% for UA376) than that observed in UA374,
and the ratio of native A21978C to A21978C(Trp13) fac-
tors was 4:6 in both genotypes, suggesting that comple-
mentation to reconstitute an active enzyme occurred in
a competitive manner.
To further explore the production of daptomycin de-
rivatives, the lptD gene, flanked downstream by seven
genes, including two or three that may be involved in
synthesis of hydroxyasparagine (hAsn) or methoxy-
aspartic acid (mOAsp), was cloned in pMF30 [27].
Recombinants carrying pMF30 produced a family of
compounds with UV and mass spectra consistent with
A21978C analogs having Ile or Val in place of Kyn13
and Glu12 or 3mGlu12 (Figure 2G; Table 2). Material for
structural confirmation was obtained by fermentations
in 7 liter vessels yielding 60 mg/l total lipopeptide. Al-
though HPLC-MS analysis of the fermentation at harvest
indicated the presence of both Glu- and 3mGlu-contain-
ing products, only the latter were present in quantities
sufficient for isolation. Each of the expected A21978C
(Ile13) and A21978C(Val13) products was purified and
identified by NMR and mass spectroscopy. Inspection
of the aromatic region of the 1H NMR spectra indicated
that the Kyn signals were absent, as was the Kyn
b-CH2 signal. Additionally, the high-field regions of the
spectra showed the presence of two extra methyl
groups for each Val- or Ile-containing product compared
to its A21978C parent. As with the cdaPS3-bearing con-
structs, the S. fradiae gene for methylation of Glu in
A54145 was not present in the complementing DNA.
That both 3mGlu- and Glu-containing A21978C(Val13)
and A21978C(Ile13) were detected confirms the flexibility
in substrate recognition, albeit at a reduced efficiency,
of the native S. roseosporus MTase.
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by Recombinants
In shake flasks, there was no adverse effect of homolo-
gous trans-complementation (pRB04) on production:
yield was essentially the same as that of the vector car-
rying positive control, UA374. Production of Trp13-
substituted compounds ranged from 30%–50% yield
compared to UA374, and the strains carrying pMF26
(cdaPS3 only) yielded 50%. The pMF23- and pMF22-
carrying strains produced 40% or 30% as much as
control, suggesting a disadvantage conferred by the
additional genes in these plasmids. Production by re-
combinants with pMF30, with lptD and seven other
genes, may also have been decreased by the presence
of the extra genes, but the 25% yield in these strains
compared to control was adequate to easily detect the
compounds and to generate enough material in 7 liter
fermentations for structure elucidation and assessment
of biological activity.
Antibacterial Activity of Recombinant Lipopeptides
Recombinants were initially assessed by indicator-
seeded patch overlays of transformants. Strains con-
taining pMF22, pMF23, and pMF26 exhibited a greater
inhibition of S. aureus growth than strains with pMF30
(Figure 4A). As whole-cell assays reflect a combination
of yield and efficacy, purified compounds were also
tested against a panel of gram-positive pathogenic bac-
teria (Figure 4B). Compounds containing Trp13 instead
of Kyn13 showed antibacterial activities similar to the
A21978C controls, but compounds containing Ile13 or
Val13 only showed comparable antibacterial activities
when coupled with the longer fatty acid tails.
Discussion
Daptomycin is the first lipopeptide antibiotic approved
for the treatment of gram-positive pathogens. Its com-
plex peptide core with unusual amino acids has pre-
sented limited opportunities for chemical modification
to produce second-generation candidates for clinical
development. To begin exploring the possibility of mak-
ing modifications in the peptide by genetically engineer-
ing the NRPS genes, we cloned and characterized the
daptomycin and A54145 biosynthetic gene clusters
[21, 27], and in this study, we developed an NRPS
trans-complementation system to generate novel com-
pounds.
Similarities in the structures of the cyclic peptides
CDA, A54145, and daptomycin, and in the organization
of their respective NRPS genes, provided a system by
which to test the engineering of daptomycin analogs
by heterologous subunit exchanges. The in vivo recon-
stitution control showed a high complementation effi-
ciency (w95%), as measured by A21978C production
in the S. roseosporus DdptD deletion strain when dptD
was expressed from an ectopic position under the con-
trol of ermEp*. This promoter was chosen because it has
been used effectively in expressing cloned secondary
metabolism genes [26, 28]. Complementation with the
terminal subunits from the other pathways led to the bio-
synthesis of active analogs of daptomycin containing
Trp13, Ile13, or Val13 at production efficiencies ranging
from 25% to 50% relative to a Kyn13 control. Theselevels were obtained without optimizing the expression
of the heterologous subunits or the fermentation condi-
tions; therefore, yield improvements should be possible
by further engineering or fermentation development. Al-
though identification and recovery of novel compounds
is simpler with a DdptD host, heterologous trans-
complementation was also observed when the cdaPS3
gene was brought into a host with a complete dpt clus-
ter. The roughly equivalent production of lipopeptides
containing Kyn13 or Trp13 indicated that the heterolo-
gous CdaPS3 subunit competed well with the native
subunit in formation of a functional hybrid NRPS multi-
subunit enzyme; in this case, the use of ermEp*probably
helped to enhance the expression of cdaPS3.
Contextual resemblances both physical (e.g., of do-
main types and order, including the Te) and biochemical
(e.g., cyclization involving an analogously positioned
Thr), as well as sequence conservation at the ends of
the subunits, must all contribute to successful comple-
mentation. Restoration of the junction structure by the
N-terminal interpeptide docking sites on the CdaPS3
and LptD proteins undoubtedly played a significant
role. It is now established that elongation of type I
Figure 4. Biological Activity of Recombinant Strains and Purified
Compounds
(A) Patch bioassay of representative strains.
(B) MIC (mg/ml) of purified compounds against a test panel.
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274polyketides, peptides, and mixed polyketide/peptides
that are assembled by PKS and NRPS mechanisms re-
quires interpeptide docking sites to facilitate the appro-
priate communication between the subunits of the giant
multisubunit enzymes [29–35]. Heterologous subunit
exchanges have been successful at generating hybrid
polyketide aglycones related to platenolide [24] and
erythronolide [25], but the molecules were not glycosy-
lated to produce active antibiotics. Our work extends
this approach for the first time to peptides in vivo, and,
in this case, the fully embellished products were active
as antibiotics. Further work is needed to establish the
relevance of the amino acid conservation and charge
distribution observed in the docking sites of DptD,
LptD, and CdaPS3, and their homologous and heter-
ologous pairing subunits, and to optimize them for
highly efficient expression of heterologous NRPS multi-
enzymes.
The results here suggest that trans-complementation
may be generalizable to other multisubunit NRPS sys-
tems if considerations are given to the design of subunit
docking sites. Where there are no convenient natural
subunits, it should be possible to follow the examples
here and build subunits with different amino acid-incor-
porating specificities, within a framework optimized for
intersubunit communication through selection of appro-
priate docking sites. Hahn and Stachelhaus [35] have
shown that this is feasible with NRPSs from Bacillus.
The potential for accessory gene involvement in gen-
erating analogs was also exemplified here. Methylation
of Glu in the Trp13-, Ile13-, or Val13-containing analogs
was accomplished by the native S. roseosporus MTase,
but, interestingly, the methylation was incomplete, as is
typical in the native production of CDA and A54145.
Whether this was an inherent limitation of the S. roseo-
sporus enzyme on the hybrid molecules, or whether
other factors precluded complete methylation, remains
to be determined.
Significance
This work demonstrates the utility of subunit trans-
complementation as a method by which to engineer
nonribosomally synthesized peptide antibiotics. In
S. roseosporus, trans-complementation of the termi-
nal dimodular daptomycin NRPS subunit with heterol-
ogous dimodular subunits was productive and robust.
This was coupled with incomplete methylation of Glu
and acylation with the three different natural fatty
acid side chains to generate 18 new lipopeptide anti-
biotics. This approach may be expanded by coupling
it with module exchanges to generate combinatorial li-
braries of lipopeptides that can also act as scaffolds
for further chemical modifications directed at the de-
velopment of second-generation derivatives of dapto-
mycin with improved therapeutic properties.
Experimental Procedures
Media
Actinomycetes were routinely grown on trypticase soy agar (TSA) or
in broth (TSB) in 125 ml flasks shaken at 200 rpm, 30ºC. Other com-
mon bacteriological media and procedures for handling organisms
are as described [36]. Agar medium AS-1 and broth media A355
and F10A were described elsewhere [21, 37]. Broth medium A354was comprised of 1% glucose, 2% soluble starch, 0.5% yeast ex-
tract, 0.5% casein, 4.6% MOPS, 0.1% antifoam A (pH 7).
Strains
UA117 is a spontaneous S. roseosporus NRRL 15998 derived mu-
tant resistant to 50 mg/ml streptomycin (C. Wai, personal communi-
cation), and was the parent for all recombinants (Table 1). S. coeli-
color M145 was used in constructing the BAC library. Escherichia
coli DH10B carrying pUZ8002 was the conjugation host for all plas-
mids. Pathogens used in bioassays (below) were from the Cubist
culture collection and are susceptible to daptomycin. Other strains
were constructed as described below.
Strain Construction
To generate a DdptD deletion host in UA117, flanking regions 50
(1.1 kb) and 30 (1.5 kb) of dptD were amplified from pCV1, a BAC
clone carrying a 128 kb insert of S. roseosporus DNA including the
entire dpt gene cluster [21], and cloned into pNEB193 to build a tar-
geting plasmid for gene replacement. The primer pairs used were
50-GCGAAGCTTCTGGTGGCGCATCACCTGG-30 and 50-GCTCTAGA
TGGAAGTATGTCCTCCATCGC-30 and 50-CGGATCCCGCCGGCAC
CTGACCC-30 and 50-CCGAATTCCGCCTCCGAGTACATCGAGG-30.
A 1.4 kb fragment including the ermE gene, conferring resistance
to 20 mg/ml lincomycin (ErmR), was amplified from Saccharopoly-
spora erythraea DNA with primers 50-CGACTAGTTTGCGCCCGA
TGCTAGTC-30 and 50-GAACTAGTCAGAGGTTGATGTCGGCCC-30,
cut with SpeI, and ligated into an XbaI site between the dpt frag-
ments. This dpt-ermE-dpt cassette was cloned into a derivative of
pRHB538 [38], a Streptomyces replicative vector with repts, aac(3)IV
for resistance to 100 mg/ml apramycin (AmR), and the S. roseospo-
rus rpsL+ gene for dominant sensitivity to streptomycin (SmS), and
it was conjugated into UA117. Selection was initially for the presence
of the plasmid (AmR) and secondarily for plasmid curing after a tem-
perature shift to 38ºC (SmR), and was followed by screening for gene
replacement (ErmR, StrR, AmS). Four candidates were confirmed as
DdptD mutants by Southern analysis [36]. UA378 was subsequently
selected as the host for conjugative transfer of the expression plas-
mids (below) that could be selected for resistance to 100 mg/ml hy-
gromycin.
Construction of Expression Plasmids
For pRB04, a 0.3 kb fragment at the start of dptD was amplified
(primers were 50-GGAATTCCATATGACGCAGCGCGCGATGG-30
and 50-GCGGATCCTTCTGCTCGGCGCCCTCG-30) from pCV1, cut
with NdeI and BamHI, and cloned into corresponding sites in
pHM11a [26]. This adapted the translational start of dptD to that pro-
vided by pHM11a and introduced the unique natural BsrGI site
within dptD. The plasmid was sequentially treated with BamHI, Kle-
now, and BsrGI, and the remainder of dptD was cloned in as a 7.2 kb
BsrGI/ScaI fragment from pCV1.
For cdaPS3 plasmids, DNA was obtained from a S. coelicolor
M145 BAC library constructed by using methods described previ-
ously [21]. The 2000 clone library was screened by PCR with primers
derived from cda (GenBank AL035654, AL035707). Clone pCV18,
with a 51 kb insert, was determined by sequencing with vector
primers P108 (50-GCCTGGCCGTCGACATTTAGG-30) and P113(50-
GGAGCTGACTGGGTTGAAGG-30) and mapping to carry the com-
plete sequence of all three cdaPS genes [9]. Complementing plas-
mids were constructed via an amplified adaptor fragment consisting
of the 50 end of the cdaPS3 gene, delimited by P177 (50-GGAATTC
CATATGGCAAGTCCGGCTTG-30) and P178 (50-CGGGATCCGACCA
TGGTGTCGATACC-30). This fragment, with a natural BsrGI site, was
cloned as an NdeI/BamHI fragment into pHM11a to build pMF21.
Fragments (13.2 kb BsrGI/BamHI, 7.6 kb BsrGI/EcoRI, and 6.9 kb
BsrGI/DraIII) containing cdaPS3 and flanking genes from pCV18
were cloned between the BsrGI and BamHI sites of pMF21 to build
pMF22, pMF23, and pMF26, respectively (inserts, vector blunt
ended with Klenow as needed).
For pMF30, a 13 kb BamHI fragment fromS. fradiae cosmid pCV15
[27] was cloned into a derivative of pHM11a in which the multiple
cloning site had been replaced (by using a mutagenic primer and
PCR) by the sequence 50-CCGTATCATATGCGCGGATCCGCTGTTC
GCCGGCAC-30. This includes the first 12 nucleotides of lptD (under-
lined), fused to the ATG start codon provided by the vector, as well
Hybrid Lipopeptide Antibiotics
275as a unique natural BamHI site from lptD suitable for cloning the
fragment from pCV15.
All plasmids were introduced into S. roseosporus strains by con-
jugation with E. coli [38]. Some of the plasmids were introduced into
UA378 and three other independently isolated DdptD mutants to
verify reproducibility, and all gave equivalent fermentation results
when complemented with pRB04, pMF22, and pMF23; therefore,
UA378 was used for all subsequent experiments. Representative
exconjugants were analyzed by Southern hybridization of EcoRI-
digested chromosomal DNA with DIG-labled pHM11a. All gave
banding patterns consistent with single plasmid insertions into
a unique IS117 insertion site. Recombinants containing plasmids in-
serted in the chromosome were grown in the presence of 100 mg/ml
hygromycin on solid agar media, but without antibiotic in liquid
culture.
Fermentation
Small-scale fermentations in 20 ml broth were conducted in 125 ml
baffled flasks shaken at 200 rpm, 30ºC: starter cultures were grown
in TSB for 48 hr, 1 ml starter culture was transferred to A355 and
grown for 24 hr for seed, and 1 ml seed was transferred into F10A
for production. Cultures were sampled 4–6 days later for HPLC anal-
ysis (below). At least two experiments were conducted on two or
more strains per genotype, and representative results are presented
in the Results. Large-scale fermentations were conducted in 7 liter
fermenters stirred at 500 rpm, aerated at 1.0 vvm, and incubated
at 30ºC. Seed stock was grown by inoculating mycelium from well-
grown plate cultures into 250 ml A355 medium in 2 liter baffled flasks
and shaken at 240 rpm at 30ºC for 24–26 hr; the entire seed culture
was transferred to a fermenter containing 5 liters A354 medium and
was harvested after 7 days.
Lipopeptide Purification and Characterization
Production cultures of UA416 (1 3 7 liters) and UA451 (2 3 7 liters)
were centrifuged to remove biomass, and broths were loaded onto
open glass columns packed with preconditioned Mitsubushi HP20
resin (60 3 300 mm) in H2O. The loaded columns were washed
with 1 liter H2O, then eluted with 2.5 liters of methanol. The eluates
were concentrated by rotary evaporation, lyophilized, and redis-
solved in water. Purification was achieved by preparative HPLC on
a Waters Prep LC system and a Waters 40 3 200 mm Symmetry
C8 6 mm radially compressed double cartridge with 40 3 10 mm
guard with a linear gradient buffered with 0.4% trifluoroacetic acid
(TFA). The gradient began with 35% (UA416) or 30% (UA451) aque-
ous acetonitrile (ACN), changed to 60% ACN over 18 min (UA416) or
20 min (UA451); the flow rate was 55 ml/min. From UA416, fractions
containing lipopeptides were collected and lyophilized to yield
76 mg A21978C1(Trp13), 72 mg A21978C2(Trp13), and 35 mg
A21978C3(Trp13). From UA451, the target components were col-
lected as six semipure fractions and lyophilized. Each was further
purified with a Symmetry C18 column (6 mm, 253 100 mm cartridge
with 25 3 10 mm guard). Application of various isocratic mobile
phase compositions (20 ml/min, buffered with 0.04% TFA) provided
the compounds of interest to >95% purity: 34% aqueous ACN
yielded 6 mg A21978C1(Val13) and 6 mg A21978C1(Ile13); 38% ACN
yielded 4 mg A21978C2(Val13), 6 mg A21978C2(Ile13), and 4 mg
A21978C3(Val13); and 36% ACN for 20 min, followed by a 10 min lin-
ear gradient to 43% can, afforded 11 mg A21978C3(Ile13). To monitor
the presence of A21978C lipopeptides in shake flasks, culture sam-
ples were centrifuged to pellet the biomass, and 20 ml broth was
analyzed by using a Waters HPLC system with a 4.63 150 mm Sym-
metry 3.5 mm column and a Phenomenex Security Guard C8 car-
tridge. The mobile phase, buffered with 0.01% TFA and flowing at
1.5 ml/min, was initially held at 10% aqueous ACN (2 min), linearly
changed to 90% ACN over 18 min, held at 90% ACN (3 min), and fol-
lowed by a wash in 10% ACN (8 min). Eluate absorbance was mon-
itored at 224 nm. Yields were estimated by reference to a daptomy-
cin standard (Cubist Pharmaceuticals, Inc., Manufacturing Dept.)
run in triplicate, and areas under the curve corresponding to identi-
fied peaks were integrated and summed after manual baseline ad-
justment. A correction factor of 0.645 for yield of A21978C3(Trp13)
with respect to daptomycin was made to allow for the relative absor-
bance at 224 nm of the new compound. Electrospray ionization liq-
uid chromatography-mass spectrometry (ESI LC-MS) was per-formed as described previously (22). 1H and 13C NMR spectra
were recorded at 308 K on a Bruker ACF400 spectrometer at
400 MHz and 100 MHz, respectively. TOCSY NMR spectra were re-
corded in CD3OD by using standard methods.
Bioassays
Strains were patched on AS-1 agar for 5 days, then overlaid with soft
nutrient agar containing CaCl2 (5 mM final) and S. aureus, and incu-
bated overnight at 37ºC. Minimum inhibitory concentrations (MICs)
of purified compounds against test organisms (below) were deter-
mined by broth microdilution according to NCCLS guidelines, ex-
cept that Mueller-Hinton broth was supplemented to 50 mg/l Ca2+
and assays were performed at 37ºC [39, 40].
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